Associate Professor Natalie Staplin
Natalie Staplin
PhD
Senior Statistician
Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences.
Natalie joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics.
Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease.
She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.
Recent publications
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Journal article
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
-
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
Journal article
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
-
A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality.
Journal article
de la Sierra A. et al, (2024), J Hypertens, 42, 1197 - 1202
-
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Journal article
Apperloo EM. et al, (2024), The lancet. Diabetes & endocrinology
-
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol